GBAF Logo
Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal
Finance

Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal

Published by Global Banking & Finance Review

Posted on May 6, 2026

1 min read

· Last updated: May 6, 2026

Add as preferred source on Google
Finance Banking Markets

Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal

Overview of Bayer's Acquisition of Perfuse Therapeutics

Acquisition Announcement

May 6 (Reuters) - Bayer said on Wednesday that it will buy biopharmaceutical company Perfuse Therapeutics to complement its ophthalmology pipeline.

Deal Structure and Financial Details

Potential Value and Payment Breakdown

The deal has a potential value of up to $2.45 billion, the company said in a statement, with a $300 million upfront payment and additional development, regulatory and commercial milestone payments based on success criteria.

Strategic Benefits and Product Pipeline

The deal will give Bayer full rights to PER-001, a small molecule endothelin receptor antagonist (ERA) in phase II clinical development, for the treatment of glaucoma and diabetic retinopathy.

Regulatory Approvals and Next Steps

Conditions for Completion

The acquisition will become effective after receiving the necessary antitrust clearances and Perfuse stockholder approvals, Bayer said.

Reporting Credits

(Reporting by Linda PasquiniEditing by David Goodman)

Key Takeaways

  • Bayer is bolstering its ophthalmology pipeline by acquiring Perfuse Therapeutics, a company developing a novel endothelin antagonist implant for eye diseases like glaucoma and diabetic retinopathy(perfusetherapeutics.com)
  • The deal structure includes $300 million upfront, with up to $2.15 billion in additional payments contingent on Perfuse meeting development, regulatory, or commercial milestones(perfusetherapeutics.com)
  • This acquisition underscores Bayer’s strategic focus on expanding into high-growth ophthalmic markets and addressing unmet medical needs in eye care(perfusetherapeutics.com)

References

Frequently Asked Questions

What is the value of Bayer's deal to acquire Perfuse Therapeutics?
The deal is valued at up to $2.45 billion, including a $300 million upfront payment and additional milestone-based payments.
Why is Bayer acquiring Perfuse Therapeutics?
Bayer is acquiring Perfuse Therapeutics to complement and strengthen its ophthalmology pipeline.
How will the payments for the Perfuse Therapeutics acquisition be structured?
Bayer will pay $300 million upfront, with further payments based on meeting development, regulatory, and commercial milestones.
When was the Bayer and Perfuse Therapeutics acquisition announced?
The acquisition was announced on May 6.

Tags

Related Articles

Image for UK's Capricorn Energy says deadline for takeover offer from Saudi's Cafani unit extended

UK's Capricorn Energy says deadline for takeover offer from Saudi's Cafani unit extended

Image for One-off plant orders lift German engineering demand in March, industry says

One-off plant orders lift German engineering demand in March, industry says

Image for Continental warns of fresh U.S. tariff blow if latest increase affects tyres

Continental warns of fresh U.S. tariff blow if latest increase affects tyres

Image for German services contract in April at fastest pace in over three years, PMI shows

German services contract in April at fastest pace in over three years, PMI shows

Image for Euro zone services activity slumps in April on weak demand, PMI shows

Euro zone services activity slumps in April on weak demand, PMI shows

Image for Italy services costs rise at fastest pace in over three years, PMI shows

Italy services costs rise at fastest pace in over three years, PMI shows

More from Finance

Explore more articles in the Finance category

Image for G7 trade ministers to discuss critical minerals supply chain, French minister says
G7 trade ministers to discuss critical minerals supply chain, French minister says
Image for France's services sector contracts further in April, final PMI shows
France's services sector contracts further in April, final PMI shows
Image for Regional leader of Spain's Canary Islands rejects hantavirus-hit cruise docking there
Regional leader of Spain's Canary Islands rejects hantavirus-hit cruise docking there
Image for German chemical mood sinks as Iran war disrupts supplies
German chemical mood sinks as Iran war disrupts supplies
Image for The Growth of Alternative Lending: What Bad Credit Loans Signal for Financial Inclusion
The Growth of Alternative Lending: What Bad Credit Loans Signal for Financial Inclusion
Image for Spain services contract for first time in nearly 3 years, PMI shows
Spain services contract for first time in nearly 3 years, PMI shows
Image for UK's Renishaw says Iran war hurting semiconductor, critical mineral supplies
UK's Renishaw says Iran war hurting semiconductor, critical mineral supplies
Image for Rail-ticketing group Trainline sees pressure from UK policy change and Iran War
Rail-ticketing group Trainline sees pressure from UK policy change and Iran War
Image for Iran says it wants a 'comprehensive agreement' with US
Iran says it wants a 'comprehensive agreement' with US
Image for Germany ponders last-ditch plan to thwart Italian bid for Commerzbank
Germany ponders last-ditch plan to thwart Italian bid for Commerzbank
Image for Kingfisher CEO Thierry Garnier to step down, join Ahold as chief
Kingfisher CEO Thierry Garnier to step down, join Ahold as chief
Image for Hungary police freeze assets, accounts in probe of Orban-era media mogul
Hungary police freeze assets, accounts in probe of Orban-era media mogul
View All Finance Posts